Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer’s disease: cohort analysis as modified primary outcome in a phase III clinical trial
Manuscript Number:
17-0560R3
Author(s):
Trevor Ahearn, Peter Bentham, Luc Bracoud, Charles S. Davis, Giovanni B. Frisoni, Serge Gauthier, Jiri H. Hardlund, Charles R. Harrington, Jianping Jia, Karin A. Kook, Ken Marek, Hans J. Moebius, Gernot Riedel, Björn O. Schelter, John Seibyl, Kohkan Shamsi, Roger T. Staff, John M.D. Storey, Vesna Vuksanovic, Gordon Wilcock, Claude M. Wischik, Damon J. Wischik
Disclosures
Trevor Ahearn
Nothing to Disclose
Peter Bentham
Sponsors:
Paid consultant - clinical advice on study design.
Responsible Officer for their Designated Body.
Lecture fee from Schwabe for lecture in Spain November 2018
Grants
Agency:
Washington University-DIAN-TU
Dates:
2016-2019
Agency:
Lundbeck
Dates:
2015-2018
Jiri H. Hardlund
Sponsors:
Chief Medical Officer, VP Clinical Development
Charles R. Harrington
Equity:
Equity held in privately listed TauRx Therapeutics Ltd
Sponsors:
Serve as Chief Scientific Officer for TauRx Therapeutics Ltd.
Patents/Royalties
I am an inventor on various pending and granted patents in the field of compounds (including LMTX and LMTM) for use in treating various conditions, including Alzheimer's disease.
Jianping Jia
Nothing to Disclose
Karin A. Kook
Consulting Fees:
Paid consultant to TauRx and other pharmaceutical companies
I have received and continue to receive honoraria as a Scientifc Advisory Board member of RODIN Therapeutics Inc., Cambridge, MA.
Equity:
I am a non-voting stockholder of the former CHASE Pharmaceuticals Corp., Washington, DC, and of RODIN Therapeutics Inc., Cambridge, MA.
Gernot Riedel
Nothing to Disclose
Björn O. Schelter
Consulting Fees:
Paid consultant of TauRx Therapeutics (Sponsor of the Study)
Grants
Agency:
GTD/TauRx
Dates:
2013-ongoing
John Seibyl
Consulting Fees:
consultant to: Piramal Imaging, Roche
Equity:
Equity in Invicro,LLC
Kohkan Shamsi
Consulting Fees:
we were a vendor for managing MRI and PET assessments in this clinical trial.
Patents/Royalties
the sponsor hired us as vendors to manage imaging assessments in this clinical trial
Roger T. Staff
Nothing to Disclose
John M.D. Storey
Equity:
Equity in privately funded TauRx Therapeutics Ltd.
Sponsors:
Chief Technical Officer, TauRx Therapeutics Ltd.
Patents/Royalties
I am an inventor on various pending and granted patents in the field of compounds (including LMTX and LMTM) for use in treating various conditions, including Alzheimer's disease. My rights in these patents have been assigned to WisTa Laboratories Ltd, an affiliate of TauRx Therapeutics Ltd.
Vesna Vuksanovic
Nothing to Disclose
Gordon Wilcock
Consulting Fees:
TauRx Advisory Board member - paid for attendance at board meetings
Sponsors:
Advisory Board member as mentioned above
Claude M. Wischik
Equity:
I hold equity in and am co-founder of TauRx Therapeutics Ltd.
Sponsors:
Executive Chairman, TauRx Therapeutics Ltd.
Patents/Royalties
An inventor on various pending and granted patents in the field of compounds (including LMTM) for use in treating various conditions, including Alzheimer's disease. Rights assigned to WisTa Laboratories Ltd, an affilliate of TauRx Therapeutics Ltd.